Introduction
============

In the 21st century, type 2 diabetes has reached epidemic proportions globally.[@ref1] It currently affects over 310 million people worldwide, and in 2014, 4.9 million deaths were attributable to diabetes related complications.[@ref1] [@ref2] Strict glycaemic control is critically important in people with type 2 diabetes. Sulphonylureas play a pivotal role in glycaemic control by stimulating insulin secretion, thereby suppressing glucose production and stimulating the utilisation of glucose.[@ref3] As a direct extension of their mechanism of action, however, the risk of hypoglycaemia is increased, and this risk may be further increased in patients with renal impairment, which is a common comorbidity associated with type 2 diabetes.

It is well established that metabolites can accumulate as the glomerular filtration rate falls. In people with type 2 diabetes, hypoglycaemia is more common among those who use long acting sulphonylureas with renally excreted active metabolites (eg, glibenclamide and glimepiride).[@ref4] [@ref5] [@ref6] [@ref7] Use of these sulphonylureas might therefore further increase the risk of hypoglycaemia in patients with renal impairment. In contrast, tolbutamide, glipizide, and gliclazide are mainly excreted as unchanged drug or inactive metabolites with minimal hypoglycaemic effect.[@ref7] As gliclazide is associated with a low risk of hypoglycaemia, it is the first choice sulphonylurea in many countries.[@ref8] [@ref9]

Studies have shown that incidence rates of hypoglycaemia in sulphonylurea users without renal impairment range from 0.2 to 1.8 events per 100 person years.[@ref10] [@ref11] [@ref12] [@ref13] For patients with renal impairment, however, the literature is sparse and conflicting. Although one study[@ref14] did not find an association in glibenclamide users, three others[@ref15] [@ref16] [@ref17] suggested an increased risk of hypoglycaemia among sulphonylurea users with renal impairment. No study has compared the risk of hypoglycaemia between the two groups of sulphonylureas---those with active metabolites and those with inactive metabolites---in patients with renal impairment.

Therefore, we evaluated the association between current use of sulphonylureas only and the risk of hypoglycaemia according to renal function and sulphonylurea metabolite group, compared with current use of metformin only.

Methods
=======

Data sources
------------

Data for this study were derived from the Clinical Practice Research Datalink (CPRD), which contains computerised medical records for more than 11 million patients from 674 practices in the United Kingdom. CPRD currently holds data on 7% of the UK population and is generalisable to the UK population.[@ref18] Data since 1987 include patients' personal characteristics, medical history, laboratory test results, details of prescriptions, specialist referrals, hospital admissions, and major outcomes, with ongoing data collection. Read codes, a hierarchical coding system, are used to define symptoms, diagnoses, referrals, and laboratory or diagnostic tests and results. Read codes are entered by the general practitioner and undergo quality checks before entry into CPRD. Diagnoses in CPRD have been validated in a wide range of diseases, including diabetes and hypoglycaemia, showing a high validity.[@ref19] [@ref20]

Study population
----------------

We included all patients aged 18 years or more with at least one prescription for a non-insulin antidiabetic agent during the period of valid CPRD data collection. For this study, data collection began in April 2004, the introduction of the Quality and Outcomes Framework, and ended in August 2012. We defined the index date as the date of the first prescription, after the start of valid data collection. In the CPRD, the date that a practice became "up to research standard" (ie, practice has medical, laboratory, and drug recording of sufficient quality for at minimum one year) largely determines the valid data collection. Therefore, all patients had a minimum of one year of high quality data collection before the index date. We applied a new user design by excluding all patients with a history of non-insulin antidiabetic agent or insulin prescriptions, or the outcome of interest, before the index date.

Use of non-insulin antidiabetic agents
--------------------------------------

Use of non-insulin antidiabetic agents was assessed in a time dependent manner. We divided follow-up in 90 day intervals, starting on the first date of an eligible prescription (ie, the index date). Use of non-insulin antidiabetic agents was assessed at the start of each 90 day time interval, and classified according to the time since the most recent prescription: current use (1-90 days), recent use (91-180 days), or past use (\>180 days). As a result, participants can move between these groups during follow-up.

We further stratified current users of sulphonylureas only according to their most recent prescribed defined daily dose (low, medium, and high), most recent renal function (≥60, 30-59, and \<30 mL/min/1.73 m^2^ or receiving dialysis), and sulphonylurea metabolite group (active versus inactive). Dosage equivalents were calculated using the World Health Organization's defined daily dosages.[@ref21] When written instructions on dosage were missing, we assigned the median value of all prescriptions. Most recent renal function was evaluated using laboratory test data (estimated glomerular filtration rate (eGFR) (modification of diet in renal disease, MDRD) where possible) and CPRD Read codes (stages of chronic kidney disease). To obtain renal function, we considered data up to one year before the start of a 90 day interval. When multiple eGFR values were reported on one day, we used the mean value. In the event of a CPRD Read code and laboratory test result being recorded on the same day, we prioritised CPRD Read codes.

Outcomes
--------

We followed patients from the index date to the end of data collection, date of transfer out of the practice area, date the practice stopped delivering data, date of death, or a first ever hypoglycaemic event; whichever occurred first. According to the methods of Bruderer et al,[@ref22] we defined a first ever hypoglycaemic event as the first Read code recording for hypoglycaemia or a laboratory test result indicating a blood glucose level of less than 3.0 mmol/L. When multiple blood glucose levels were recorded on the same day, we used the lowest value. Patients were excluded if they had a history of a hypoglycaemic event before their index date.

Potential confounders
---------------------

We assessed the presence of risk factors for hypoglycaemia during follow-up by reviewing computerised medical records for any record of a risk factor before the start of an interval. Several potential confounders were determined at baseline: sex, smoking status (non-smoker, current smoker, former smoker, or unknown), and body mass index (\<25.0, 25.0--29.9, ≥30 kg/m^2^, or unknown). Other confounders considered in this study were determined time dependently at the start of each new interval; alcohol use, the most recent haemoglobin A1~c~ record in the past year, chronic liver disease, cardiovascular disease, congestive heart failure, or cognitive impairment or dementia. In addition, we considered use of any of the following drugs in the previous six months of an interval as a potential confounder: oral anticoagulants, statins, antipsychotics or antidepressants, corticosteroids, antihypertensives (including loop diuretics, thiazide diuretics, renin-angiotensin-aldosterone system inhibitors (angiotensin converting enzyme inhibitors or angiotensin receptor blockers), calcium channel blockers, and β blockers[@ref23]), and non-steroidal anti-inflammatory drugs. Confounders are factors associated with hypoglycaemia and the exposure of interest (sulphonylurea use or renal function) and we selected them based on the literature. We entered confounders into the final model if they independently changed the β coefficient for current sulphonylurea use by at least 5% or when inclusion was supported by clinical evidence, or both.

Data analysis
-------------

We identified and summarised incidence rates as events per 1000 person years. The primary analysis was to estimate the risk of hypoglycaemia in current users of sulphonylureas only compared with current users of metformin only in relation to renal function. This analysis was further stratified by prescribed daily dose, sulphonylurea metabolite (active versus inactive), and specific sulphonylurea. We used Cox regression analysis (SAS 9.2. PHREG procedure) in all analyses.

Sensitivity analyses
--------------------

Additional sensitivity analyses were requested during peer review, and the following post hoc analyses were completed: stratification of current users of metformin only by renal function, and stratification of current users of sulphonylureas only by daily dose and haemoglobin A1~c~ level: low (\<7%) versus high (≥7%).

Patient involvement
-------------------

Patients were not involved in the development of the research question, outcome measures, design, or implementation of the study. Patients were not asked to advise, interpret, or disseminate results. However, we plan on sharing our findings with the European Diabetes Association.

Results
=======

Table 1[](#tbl1){ref-type="table"} shows the baseline characteristics of all 120 803 patients (see supplementary appendix for stratification by drugs at the index date). The mean duration of follow-up was 3.7 years. The mean age of all users was 67.4 years, and 47.2% (n=57 065) were women. No substantial differences were observed in age and sex distribution across drug use groups (see supplementary appendix A). However, the proportion of patients with a high body mass index (≥30) was considerably lower in sulphonylurea users (26.8%; n=3544) compared with metformin users (57.1%; n=52 496) or other non-insulin antidiabetic agents (57.9%; n=3628). More sulphonylurea users had lower renal function than metformin users or users of other non-insulin antidiabetic agents. Similarly, cardiovascular diseases were more prevalent in sulphonylurea users compared with the other groups.

###### 

Baseline characteristics of users of non-insulin antidiabetic agents. Values are numbers (percentages) unless stated otherwise

  Characteristics                                               Users of non-insulin antidiabetes agents (n=120 803)   
  ------------------------------------------------------------- ------------------------------------------------------ --
  Mean (SD) follow-up time                                      3.65 (2.4)                                             
  Women                                                         57 065 (47.2)                                          
  Mean (SD) age (years)                                         67.4 (16.0)                                            
  Age group (years):                                                                                                   
   18-29                                                        2127 (1.8)                                             
   30-39                                                        4014 (3.3)                                             
   40-49                                                        10 157 (8.4)                                           
   50-59                                                        19 319 (16.0)                                          
   60-69                                                        27 815 (23.0)                                          
   70-79                                                        29 042 (24.0)                                          
   ≥80                                                          28 329 (23.5)                                          
  Most recent renal function in past year (mL/min/1.73 m^2^):                                                          
   \<30                                                         734 (0.6)                                              
   30-59                                                        19 070 (15.8)                                          
   ≥60                                                          60 025 (49.7)                                          
   Unknown                                                      40 974 (33.9)                                          
  Mean (SD) haemoglobin A1~c~ (%)                               8.32 (1.86)                                            
  Unknown                                                       57 850 (47.9)                                          
  Smoking status:                                                                                                      
   Current smoker                                               22 007 (18.2)                                          
   Former smoker                                                49 598 (41.1)                                          
   Never smoker                                                 48 328 (40.0)                                          
   Unknown                                                      870 (0.7)                                              
  Alcohol use:                                                                                                         
   Yes                                                          77 880 (64.5)                                          
   No                                                           35 427 (29.3)                                          
   Unknown                                                      7496 (6.2)                                             
  Body mass index:                                                                                                     
   \<20.0                                                       1670 (1.4)                                             
   20.0-24.9                                                    14 759 (12.2)                                          
   25.0-29.9                                                    36 907 (30.6)                                          
   ≥30.0                                                        63 770 (52.8)                                          
   Unknown                                                      3697 (3.1)                                             
  History of disease:                                                                                                  
   Asthma or COPD                                               18 698 (15.5)                                          
   Cardiovascular disease                                       18 863 (15.6)                                          
   Chronic liver disease                                        321 (0.3)                                              
   Cognitive impairment or dementia                             1767 (1.5)                                             
  Drug use in past six months:                                                                                         
   Thiazide diuretics                                           20 689 (17.1)                                          
   RAAS inhibitors                                              43 611 (36.1)                                          
   Loop diuretics                                               10 918 (9.0)                                           
   β blockers                                                   20 843 (17.3)                                          
   Calcium channel blockers                                     23 963 (19.8)                                          
   Typical antipsychotics                                       1079 (0.9)                                             
   Atypical antipsychotics                                      1693 (1.4)                                             
   SSRIs                                                        9159 (7.6)                                             
   SNRIs                                                        1491 (1.2)                                             
   Tricyclic antidepressants                                    7276 (6.0)                                             
   Monoamine oxidase inhibitors                                 22 (0.02)                                              
   NSAIDs                                                       15 471 (12.8)                                          
   Statins                                                      50 925 (42.2)                                          
   Corticosteroids (systemic)                                   6185 (5.1)                                             
   Oral anticoagulants                                          4620 (3.8)                                             
   Trimethoprim                                                 4838 (4.0)                                             

COPD=chronic obstructive pulmonary disease; NSAIDs=non-steroidal anti-inflammatory drugs; RAAS=renin-angiotensin-aldosterone system; SSRIs=selective serotonin reuptake inhibitors; SNRIs=serotonin-norepinephrine reuptake inhibitors.

We identified a 2.5-fold increased risk of a hypoglycaemic event among current users of sulphonylureas only compared with current users of metformin only (adjusted hazard ratio 2.50, 95% confidence interval 2.23 to 2.82), adjusted for use of other non-insulin antidiabetic agents (table 2[](#tbl2){ref-type="table"}). The risk was further increased among patients who used sulphonylureas and metformin concomitantly. When current sulphonylurea use was stratified by prescribed daily dose, a more than threefold increased risk of hypoglycaemic events was found among users of the highest daily dose (3.12, 2.68 to 3.62) compared with users of metformin only.

###### 

Risk of hypoglycaemia in participants with diabetic using non-insulin antidiabetic agents (NIAAs), sulphonylurea only users stratified by most recent prescribed daily dose

  Drug use                               Risk of hypoglycaemia                                          
  -------------------------------------- ----------------------- --------- ------ --------------------- ---------------------
  **Metformin only use**                                                                                
  Current                                836                     205 351   4.1    Reference             Reference
  Recent                                 20                      21 584    0.9    0.37 (0.24 to 0.57)   0.36 (0.23 to 0.55)
  Past                                   47                      673 009   0.1    0.18 (0.14 to 0.24)   0.18 (0.14 to 0.25)
  **Sulphonylurea only use**                                                                            
  Current‡:                              457                     33 829    13.5   3.30 (2.94 to 3.69)   2.50 (2.23 to 2.82)
   Low dose                              146                     15 236    9.6    2.68 (2.35 to 3.06)   2.03 (1.77 to 2.32)
   Medium dose                           109                     8988      12.1   2.81 (2.43 to 3.24)   2.16 (1.86 to 2.50)
   High dose                             102                     4386      23.3   4.18 (3.61 to 4.84)   3.12 (2.68 to 3.62)
   Unknown§                              100                     3808      26.3   5.88 (5.02 to 6.87)   4.60 (3.92 to 5.40)
  Recent                                 17                      3734      4.6    1.53 (0.95 to 2.48)   1.09 (0.67 to 1.76)
  Past                                   43                      78 383    0.6    0.74 (0.55 to 1.01)   0.56 (0.41 to 0.76)
  **Metformin and sulphonylurea use**                                                                   
  Current                                1043                    74 847    13.9   3.24 (2.95 to 3.56)   3.06 (2.79 to 3.37)
  Recent                                 16                      6187      2.6    1.15 (0.68 to 1.97)   1.05 (0.62 to 1.78)
  Past                                   58                      447 723   0.1    0.44 (0.34 to 0.58)   0.40 (0.30 to 0.52)
  **Metformin and other NIAA use**                                                                      
  Current                                124                     19 652    6.3    1.26 (1.00 to 1.59)   1.28 (1.02 to 1.61)
  Recent                                 \<6                     594       6.7    0.80 (0.23 to 2.84)   0.83 (0.23 to 2.92)
  Past                                   \<6                     3850      0.1    0.17 (0.06 to 0.45)   0.17 (0.06 to 0.47)
  **Sulphonylurea and other NIAA use**                                                                  
  Current                                82                      4830      17.0   3.69 (2.83 to 4.80)   3.12 (2.39 to 4.06)
  Recent                                 \<6                     425       4.7    1.25 (0.25 to 6.18)   1.05 (0.21 to 5.20)
  Past                                   \<6                     7822      0.4    0.52 (0.17 to 1.62)   0.41 (0.13 to 1.30)
  **Other NIAA use¶**                                                                                   
  Current                                32                      4700      6.8    0.88 (0.74 to 1.04)   0.93 (0.79 to 1.10)
  Recent                                 \<6                     357       5.6    1.45 (0.64 to 3.25)   1.44 (0.64 to 3.20)
  Past                                   \<6                     876       1.1    1.37 (1.21 to 1.56)   1.37 (1.21 to 1.55)

Current use=in previous 90 days from start of a 90 day interval; recent use=between 91 and 180 days from start of a 90 day interval; past use=more than 180 days from start of a 90 day interval. All analyses adjusted for current, recent, past use of all drug use groups.

\*Adjusted for age and sex.

†Adjusted for age, sex, body mass index, alcohol use, smoking status, cardiovascular disease, chronic heart failure, and use of loop diuretics.

‡Sulphonylurea only use stratified by most recent dose: low dose, \<5 mg glibenclamide equivalents; medium dose, 5-10 mg glibenclamide equivalents; high dose, \>10 mg glibenclamide equivalents.

§Patients only received one prescription; a minimum of two are required to estimate the prescribed daily dose.

¶Other than sulphonylurea and metformin use.

Table 3[](#tbl3){ref-type="table"} shows that the risk of hypoglycaemic events also increased with reduced renal function. Patients with an eGFR of less than 30 mL/min/1.73 m^2^ using sulphonylureas only had a fivefold increased risk compared with users of metformin only (4.96, 3.76 to 6.55), whereas this risk was noticeably lower among patients with an eGFR of 30-59 mL/min/1.73 m^2^ (2.69, 2.25 to 3.20) or ≥60 mL/min/1.73 m^2^ (2.04, 1.73 to 2.41).

###### 

Risk of hypoglycaemia in current users of sulphonylureas only compared with current users of metformin only; current sulphonylurea only users stratified by renal function and active versus inactive metabolites

  NIAA use                                    Risk of hypoglycaemia                                           
  ------------------------------------------- ----------------------- --------- ------ ---------------------- ----------------------
  Current metformin only                      836                     205 351   4.1    Reference              Reference
  Current sulphonylurea only                  457                     33 829    13.5   3.30 (2.94 to 3.69)    2.50 (2.23 to 2.82)
  Renal function \<30 mL/min/1.73 m^2^:       56                      1702      32.9   7.98 (6.08 to 10.46)   4.96 (3.76 to 6.55)
   Sulphonylureas with active metabolites     \< 6                    110       9.7    2.24 (0.32 to 15.94)   1.48 (0.21 to 10.52)
   Sulphonylureas with inactive metabolites   55                      1517      36.3   8.41 (6.40 to 11.05)   5.20 (3.94 to 6.88)
  Renal function 30-59 mL/min/1.73 m^2^:      156                     10 143    15.4   3.79 (3.19 to 4.49)    2.69 (2.25 to 3.20)
   Sulphonylureas with active metabolites     17                      906       18.8   4.65 (2.88 to 7.52)    3.48 (2.15 to 5.64)
   Sulphonylureas with inactive metabolites   138                     8837      15.6   3.68 (3.08 to 4.41)    2.60 (2.16 to 3.13)
  Renal function ≥60 mL/min/1.73 m^2^:        174                     16 711    10.5   2.52 (2.14 to 2.97)    2.04 (1.73 to 2.41)
   Sulphonylureas with active metabolites     19                      1562      12.7   2.91 (1.85 to 4.59)    2.46 (1.56 to 3.88)
   Sulphonylureas with inactive metabolites   155                     14 466    10.7   2.48 (2.09 to 2.95)    2.01 (1.69 to 2.39)
  Unknown                                     71                      5274      13.5   3.32 (2.60 to 4.23)    2.63 (2.06 to 3.36)

NIAA=non-insulin antidiabetic agent. Current use=in previous 90 days from start of a 90 day interval.

Results are corrected for all other possible combinations of NIAA use (see table 2[](#tbl2){ref-type="table"}).

\*Adjusted for age and sex.

†Adjusted for age, sex, body mass index, alcohol use, smoking status, cardiovascular disease, chronic heart failure and use of loop diuretics.

No substantial differences in risk were observed between sulphonylureas with active metabolites and those with inactive metabolites, with hazard ratios estimating a similar twofold to threefold increase in risk (tables 3 and 4[](#tbl3 tbl4){ref-type="table"}). It seems that the risk of hypoglycaemic events was highest among current users of sulphonylureas with active metabolites. As there were fewer outcomes, however, this analysis had limited power. Particularly, there were insufficient numbers of current users of sulphonylureas with active metabolites and an eGFR less than 30 mL/min/1.73 m^2^ to make a valid comparison in patients with chronic kidney disease stage 4 or 5.

###### 

Risk of hypoglycaemia in current users of sulphonylureas only compared with current users of metformin only; current sulphonylurea only users stratified by type of sulphonylurea

  NIAA use                                   Risk of hypoglycaemia                                           
  ------------------------------------------ ----------------------- --------- ------ ---------------------- ----------------------
  Current metformin only use                 836                     205 351   4.1    Reference              Reference
  Current sulphonylurea only use             457                     33 829    13.5   3.30 (2.94 to 3.69)    2.50 (2.23 to 2.82)
  Sulphonylureas with active metabolites:    50                      3241      15.4   3.60 (2.70 to 4.78)    2.91 (2.18 to 3.87)
   Glimepiride                               28                      2629      10.7   2.46 (1.69 to 3.59)    1.97 (1.35 to 2.87)
   Glibenclamide                             22                      610       36.1   8.76 (5.73 to 13.39)   7.48 (4.89 to 11.44)
  Sulphonylurea with inactive metabolites:   406                     29 141    13.9   3.26 (2.90 to 3.67)    2.46 (2.18 to 2.78)
   Glipizide                                 14                      1273      11.0   2.61 (1.54 to 4.43)    2.11 (1.24 to 3.58)
   Tolbutamide                               \<6                     410       7.3    1.75 (0.56 to 5.42)    1.24 (0.40 to 3.87)
   Gliclazide                                389                     27 433    14.2   3.32 (2.94 to 3.74)    2.50 (2.21 to 2.83)
  Combination of metabolites                 \<6                     64        15.7   3.75 (0.53 to 26.68)   2.65 (0.37 to 18.86)

NIAA=non-insulin antidiabetic agent.

Results are corrected for all other possible combinations of NIAA use (see table 2[](#tbl2){ref-type="table"}). Current use=in previous 90 days from start of a 90 day interval.

\*Adjusted for age and sex.

†Adjusted for age, sex, body mass index, alcohol use, smoking status, cardiovascular disease, chronic heart failure, and use of loop diuretics.

When we stratified further to individual sulphonylureas, our results showed that use of glibenclamide was associated with the highest risk of hypoglycaemic events (7.48, 4.89 to 11.44) compared with current use of metformin (table 4[](#tbl4){ref-type="table"}). Gliclazide use, often recommended as the first choice sulphonylurea, did not coincide with a significantly lower risk, as it appeared to be similar to the risk of glimepiride, glipizide, and tolbutamide.

Sensitivity analyses
--------------------

In a post hoc analysis we compared current users of metformin only with renal impairment to current users of sulphonylureas only with renal impairment (see supplementary appendix B). Compared with users of metformin only with low renal function, users of sulphonylureas only with low renal function had a fourfold increase in risk for a hypoglycaemic event (4.12, 2.72 to 6.25). When current use of sulphonylureas only was stratified by daily dose and high or low haemoglobin A1~c~ values (see supplementary appendix C), we identified that patients with a high daily dose (\>10 mg glibenclamide equivalents) and low haemoglobin A1~c~ value (\<7%) had an increased risk of hypoglycaemic events (4.88, 3.40 to 6.99).

Discussion
==========

Compared with current use of metformin only, current use of sulphonylureas only was associated with an increased risk of hypoglycaemic events, and this risk was increased in patients with a high prescribed daily dose and stage 4 or 5 chronic kidney disease. We also identified a similar risk of hypoglycaemia between current users of sulphonylureas with active or inactive metabolites. Interestingly, gliclazide is the first choice sulphonylurea in many countries, as it is associated with lower rates of hypoglycaemia, yet in our study we did not observe a decreased risk compared with glimepiride, glipizide, and tolbutamide. This could greatly influence the treatment decision making process of doctors and should be investigated further.

We found a 2.5-fold increased risk of hypoglycaemic events in current users of sulphonylureas only compared with current users of metformin only. This is consistent with the UK Prospective Diabetes Study and the studies by Ben Salem et al and Bodmer et al.[@ref24] [@ref25] [@ref26] Results also confirmed an increased risk when sulphonylureas were used in combination with metformin or with other non-insulin antidiabetic agents,[@ref26] and also among patients receiving a high sulphonylurea dose.

Our study provides an important addition to the existing literature by providing new information about the role of renal function and different sulphonylureas on risk of hypoglycaemic events. When patients were stratified by renal function, an eGFR of less than 30 mL/min/1.73 m^2^ was associated with a significantly increased risk of a hypoglycaemic event in users of sulphonylureas only, suggesting that impaired renal function is a risk factor for hypoglycaemia. Schloot et al[@ref17] reported similar results for risk of severe hypoglycaemia (requiring third party assistance). However, results were not generalisable to general care, as the study population consisted of patients treated in specialised diabetes centres. Therefore, our study is the first with real life data on the rates of hypoglycaemic events in patients with renal impairment during routine sulphonylurea treatment in general clinical practice.

Remarkably, the results showed no difference between current users of sulphonylureas with active metabolites and those with inactive metabolites. Because of the mechanism of action, we expected sulphonylureas with active metabolites to show an increased risk, yet found no conclusive evidence of this. However, it is noteworthy that among sulphonylurea users with renal impairment most hypoglycaemic events were among those receiving sulphonylureas with inactive metabolites, limiting comparisons with active metabolites. Moreover, among sulphonylureas with active metabolites, the risk of hypoglycaemic events was lower in current users of glimepiride compared with current users of glibenclamide (twofold *v* 7.5-fold increase); however, we were unable to stratify this by renal function. Several underlying mechanisms might explain the difference between glibenclamide and glimepiride. The active metabolite of glimepiride has less hypoglycaemic effect than the parent drug,[@ref7] and glimepiride is known to exhibit a higher exchange rate and lower binding affinity to the pancreatic β cells than glibenclamide.[@ref27] [@ref28] Thus, although not affecting treatment efficacy, smaller amounts of insulin are secreted in the fasting state or postprandially with use of glimepiride compared with glibenclamide.[@ref29] [@ref30]

While unexpected, one of our most interesting findings is that gliclazide may not be accompanied by a lower risk of hypoglycaemia compared with other sulphonylureas. Gliclazide is a sulphonylurea of first choice in many countries, including the UK, the Netherlands, and Canada, as it is assumed to be associated with a lower risk of hypoglycaemia and lower mortality and morbidity compared with other sulphonylureas.[@ref8] [@ref9] A meta-analysis of 25 randomised controlled trials found a lower proportion of glicalazide users at risk of hypoglycaemia (0.1%) compared with users of other sulphonylureas (0.9-15.5%).[@ref9] However, as is often the case, participants in randomised controlled trials may not be representative of the general population with type 2 diabetes receiving sulphonylureas in clinical practice (eg, age, general state of health, and comorbidities, including renal impairment). Results from two observational studies suggest that severe hypoglycaemic events are uncommon among gliclazide users,[@ref31] [@ref32] although the number of patients in these studies was relatively low (800 and 1397, respectivly). Thus, although in contrast with the findings of previous studies,[@ref8] [@ref9] the results of this large real world cohort suggest that gliclazide may not be superior to other sulphonylureas. This result could greatly impact the current clinical decision making for diabetes care, and should therefore be further assessed, particularly in relation to renal function.

In addition to those already mentioned, the study has some limitations. Firstly, we were unable to identify patients with mild hypoglycaemia that was corrected at home with glucose. Consequently, we expect our results may be an underestimation of the overall incidence of hypoglycaemia. We excluded patients with a history of a hypoglycaemic event before the index date, as this is risk factor for a second event and these patients may have experienced in home management. While this may have resulted in an underestimation of hypoglycaemia, we do not believe the misclassification of mild outcomes to be differential between metformin users and sulphonylurea users. Moreover, non-differential misclassification would result in masking the true effect (bias towards the null) leading to insignificant findings. As we found a significant association, we do not believe our main conclusions are influenced by the potential non-differential misclassification of outcome. A second, and similar, limitation was the inability to distinguish severe hypoglycaemia from mild hypoglycaemia. In light of this, we completed a post hoc analysis using CPRD Read codes for admission to hospital or visit to an emergency room as a proxy indicator of severity (data not shown). However, there were few cases where the hypoglycaemic event date and the date of hospital admission or emergency room visit were identical. As we cannot confirm the reason for hospital admission, it presumably led to misclassification, in particular for identifying severe cases. We therefore encourage future research to examine further the differences between severe and mild hypoglycaemic events in sulphonylurea users with renal impairment.

A third limitation was that two prescriptions are required to estimate the prescribed daily dose. A patient had to have sufficient follow-up time in the database before an event (or censoring) to estimate the given daily dose (at least six months), otherwise the dose was reported as unknown. However, there was no indication that doses were selectively missing in one of the three groups (low, medium, or high dose). Similarly, there is the potential that missing data on lifestyle factors, such as body mass index and smoking, may have introduced bias. Missing data can be dealt with in many ways, including, as in our analysis, the use of an indicator variable for "missingness." Another option is the so called complete case analysis, where only patients with complete information on all confounders are included. Both methods were examined, and results and interpretation were similar (data not shown). Fourthly, although there were many hypoglycaemic events in our database, we did not have adequate statistical power to stratify current sulphonylurea only users by type of sulphonylurea, renal function, and average prescribed daily dose. Similarly, the number of events (\<6) in the sulphonylurea group with active metabolites and chronic kidney disease stage 4 or 5 was low. This may explain the absence of the expected higher risk of hypoglycaemic events in this group. Fifthly, there is the potential for off-label use of metformin in women of reproductive age with polycystic ovarian syndrome; however, in a sensitivity analysis excluding all affected women (n=82) at baseline (data not shown), results were unchanged.

Finally, there is the potential for residual confounding. While participants of randomised controlled trials are highly selected and randomly allocated to one of the treatment options, this is not the case in general practice. Indeed, our data show that metformin users were characterised by higher body mass index and renal clearance compared with sulphonylurea users at baseline, although this is not unexpected. To tackle this, we adjusted or stratified our analysis by the most important clinical risk factors (body mass index, renal function, and age), yet we acknowledge that we were unable to correct for all potential confounders, such as autonomic neuropathy, exercise,[@ref33] and amount of alcohol consumption.[@ref34]

A major strength of this study is the long follow-up period in a large database, representative of the total UK population. As information is present for a wide range of confounding factors, such as smoking status, body mass index, and comorbidities, we were able statistically to adjust our results for several potentially important confounders. We were also able to classify drug use and covariates in a time varying classification. Although we were unable to identify severity, the evaluation of hypoglycaemia using Read codes results in a lower chance of overestimating the risk of hypoglycaemic events compared with glucose levels. Additionally, we excluded patients with a history of hypoglycaemic events, as a previous episode of hypoglycaemia is known to increase the risk of a second event.[@ref35] Finally, we employed a new user design, which eliminates the influence of previous treatment.

Conclusions
-----------

The findings of this large observational study suggest that the risk of hypoglycaemia is significantly increased in current users of sulphonylureas only with severe renal impairment compared with users of metformin only. Moreover, the results of this study provide evidence that the use of high sulphonylurea doses should be considered with caution in patients with renal impairment. Interestingly, we did not find evidence of superiority of gliclazide to other sulphonylureas in reducing the risk of hypoglycaemia compared with metformin users. Since current guidelines suggest gliclazide as the first choice in many countries, the findings of this study provide grounds for further investigation as they may have a substantial impact on current clinical decision making in diabetes care.

### What is already known on this topic

1.  Hypoglycaemia is a well known side effect of treatment with sulphonylureas

2.  Gliclazide is the first choice sulphonylurea for type 2 diabetes in many countries as it is associated with a lower risk of hypoglycaemia

3.  Data on the incidence of hypoglycaemia in sulphonylurea treated patients with impaired renal function are sparse and conflicting

### What this study adds

1.  The risk of a hypoglycaemic event is significantly increased in sulphonylurea only users with severe renal impairment receiving general care

2.  The risk of hypoglycaemia did not differ between users of sulphonylureas with active metabolites and users of sulphonylureas with inactive metabolites

3.  Our study does not confirm current guidelines that suggest the superiority of gliclazide to other sulphonylureas in reducing the risk of hypoglycaemia
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